CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
|Articles|May 14, 2018
Healthcare Robotics: Meet Mabu Your Personal Health Companion
Author(s)Michelle Maskaly
Take a sneak peek at what the future of home healthcare could look like with the use of robotics and artificial intelligence.
Advertisement
Cory Kidd, founder and CEO of
Advertisement
Related to this article
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
2
Where GLP-1 Development May be Headed
3
Connecting RWD to Better Understand the Patient Journey
4
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
5